411 related articles for article (PubMed ID: 31028836)
21. Development of Fluorophore-Labeled Thailanstatin Antibody-Drug Conjugates for Cellular Trafficking Studies.
Kulkarni C; Finley JE; Bessire AJ; Zhong X; Musto S; Graziani EI
Bioconjug Chem; 2017 Apr; 28(4):1041-1047. PubMed ID: 28191936
[TBL] [Abstract][Full Text] [Related]
22. Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
Birrer MJ; Moore KN; Betella I; Bates RC
J Natl Cancer Inst; 2019 Jun; 111(6):538-549. PubMed ID: 30859213
[TBL] [Abstract][Full Text] [Related]
23. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug Conjugates.
Khera E; Thurber GM
BioDrugs; 2018 Oct; 32(5):465-480. PubMed ID: 30132210
[TBL] [Abstract][Full Text] [Related]
25. Catabolism of antibody drug conjugates and characterization methods.
Shadid M; Bowlin S; Bolleddula J
Bioorg Med Chem; 2017 Jun; 25(12):2933-2945. PubMed ID: 28438386
[TBL] [Abstract][Full Text] [Related]
26. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
[TBL] [Abstract][Full Text] [Related]
27. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
28. Antibody drug conjugates: Progress, pitfalls, and promises.
Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
[TBL] [Abstract][Full Text] [Related]
29. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
[TBL] [Abstract][Full Text] [Related]
30. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
Frigerio M; Kyle AF
Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
[TBL] [Abstract][Full Text] [Related]
31. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
Singh D; Dheer D; Samykutty A; Shankar R
J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
[TBL] [Abstract][Full Text] [Related]
32. Toward a Ferrous Iron-Cleavable Linker for Antibody-Drug Conjugates.
Spangler B; Kline T; Hanson J; Li X; Zhou S; Wells JA; Sato AK; Renslo AR
Mol Pharm; 2018 May; 15(5):2054-2059. PubMed ID: 29569925
[TBL] [Abstract][Full Text] [Related]
33. Antibody drug conjugates: Design implications for clinicians.
Pang S; Duong A; Siu C; Indorf A
J Oncol Pharm Pract; 2024 Jul; 30(5):907-918. PubMed ID: 38651308
[TBL] [Abstract][Full Text] [Related]
34. [Design of next generation antibody drug conjugates].
Zhu GD; Fu YX
Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
Kamath AV; Iyer S
Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
[TBL] [Abstract][Full Text] [Related]
36. The clinical development of antibody-drug conjugates - lessons from leukaemia.
Jabbour E; Paul S; Kantarjian H
Nat Rev Clin Oncol; 2021 Jul; 18(7):418-433. PubMed ID: 33758376
[TBL] [Abstract][Full Text] [Related]
37. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
[TBL] [Abstract][Full Text] [Related]
38. Contribution of linker stability to the activities of anticancer immunoconjugates.
Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
[TBL] [Abstract][Full Text] [Related]
39. FRET Reagent Reveals the Intracellular Processing of Peptide-Linked Antibody-Drug Conjugates.
Lee BC; Chalouni C; Doll S; Nalle SC; Darwish M; Tsai SP; Kozak KR; Del-Rosario G; Yu SF; Erickson H; Vandlen R
Bioconjug Chem; 2018 Jul; 29(7):2468-2477. PubMed ID: 29856915
[TBL] [Abstract][Full Text] [Related]
40. Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.
Stagg NJ; Shen BQ; Brunstein F; Li C; Kamath AV; Zhong F; Schutten M; Fine BM
Regul Toxicol Pharmacol; 2016 Dec; 82():1-13. PubMed ID: 27773754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
